Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.46 |
| ▸ | F11 | P03951 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839928 | 0.82 | LPL (0.41) | LPLLIPGF11ESR2ENPP2 | |
| SCHEMBL14659551 | 0.77 | L3MBTL1 (0.55) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL18954100 | 0.77 | L3MBTL1 (0.51) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL16880416 | 0.76 | POLB (0.54) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL2239353 | 0.75 | LPL (0.44) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL23242449 | 0.74 | LPL (0.43) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL838675 | 0.74 | ENPP2 (0.43) | ENPP2 | |
| SCHEMBL7212064 | 0.74 | ENPP2 (0.53) | ENPP2F2 | |
| SCHEMBL23242460 | 0.73 | LIPG (0.43) | LPLLIPGF11ESR2CA1 | |
| SCHEMBL23533584 | 0.73 | L3MBTL1 (0.46) | LPLLIPGF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139576-B2 | Aminomethyl biaryl benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139576-B2 | Aminomethyl biaryl benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139576-B2 | Aminomethyl biaryl benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2704573-A1 | AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20140066443-A1 | AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2014-03-06 | — | — | US | disclosed |
| US-20140066443-A1 | AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2014-03-06 | — | — | US | disclosed |
| US-20140066443-A1 | AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2014-03-06 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| WO-2012151136-A1 | AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151136-A1 | AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-2496569-A2 | HETEROCYCLIC DERIVATIVES | MSD Oss B.V. (NL) | 2012-09-12 | — | — | EP | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066443-A1 | AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES | GRM2, GRM3, GRIN2C | LPL 3678/4885LIPG 4225/4885F11 4808/4885 |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIN3A, GRIN2D | LPL 3915/4885LIPG 4809/4885F11 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.